- Home
- BOLT vs SNSE Comparison
BOLT vs SNSE Comparison
Compare BOLT & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLT
- SNSE
- Stock Information
- Founded
- BOLT 2015
- SNSE 2005
- Country
- BOLT United States
- SNSE United States
- Employees
- BOLT N/A
- SNSE N/A
- Industry
- BOLT Biotechnology: Pharmaceutical Preparations
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- BOLT Health Care
- SNSE Health Care
- Exchange
- BOLT Nasdaq
- SNSE Nasdaq
- Market Cap
- BOLT 9.4M
- SNSE 10.5M
- IPO Year
- BOLT 2021
- SNSE 2021
- Fundamental
- Price
- BOLT $5.32
- SNSE $9.02
- Analyst Decision
- BOLT Buy
- SNSE Strong Buy
- Analyst Count
- BOLT 3
- SNSE 4
- Target Price
- BOLT $47.50
- SNSE $72.50
- AVG Volume (30 Days)
- BOLT 10.9K
- SNSE 8.3K
- Earning Date
- BOLT 11-11-2025
- SNSE 11-13-2025
- Dividend Yield
- BOLT N/A
- SNSE N/A
- EPS Growth
- BOLT N/A
- SNSE N/A
- EPS
- BOLT N/A
- SNSE N/A
- Revenue
- BOLT $4,167,000.00
- SNSE N/A
- Revenue This Year
- BOLT N/A
- SNSE N/A
- Revenue Next Year
- BOLT N/A
- SNSE N/A
- P/E Ratio
- BOLT N/A
- SNSE N/A
- Revenue Growth
- BOLT N/A
- SNSE N/A
- 52 Week Low
- BOLT $4.59
- SNSE $5.00
- 52 Week High
- BOLT $14.36
- SNSE $17.40
- Technical
- Relative Strength Index (RSI)
- BOLT 51.15
- SNSE 57.43
- Support Level
- BOLT $5.00
- SNSE $7.93
- Resistance Level
- BOLT $5.50
- SNSE $9.50
- Average True Range (ATR)
- BOLT 0.22
- SNSE 0.57
- MACD
- BOLT 0.05
- SNSE 0.09
- Stochastic Oscillator
- BOLT 74.06
- SNSE 74.19
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).